Lasa Supergenerics Limited
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.
What Lasa files
- Others40
- Board Meeting18
- Important15
- Results5
- Updates5
Lasa Supergenerics incurred fines totaling Rs. 202,960 from BSE & NSE due to several compliance delays. These included gaps in Company Secretary appointment and late submissions of shareholding patterns, shareholder complaints, and corporate governance reports.
Lasa Supergenerics confirmed it does not qualify as a 'Large Corporate' for specific debt fundraising requirements, implying a potentially simpler compliance path for future debt issuance.
LASA Supergenerics reported a Q1 net loss of ₹8.26 Cr. Operations ceased after a factory fire caused an uninsured exceptional loss of ₹20.57 Cr. The company, unable to restart manufacturing, is exploring contract production or leasing facilities amidst going concern uncertainty.
LASA Supergenerics announced its fire-affected manufacturing facility cannot resume operations due to ongoing clearance and operational challenges. The company is actively exploring alternative solutions, including contract manufacturing arrangements or leasing the facility. This move aims to mitigate business disruption and ensure continued production. Investors should note this significant operational shift...
Lasa Supergenerics Limited has informed the Exchange about General Updates